MAIN CONTENT
A first for federal research
The FDA said the Department of Health and Human Services is funding early-stage trials through the Advanced Research Projects Agency for Health, known as ARPA-H, and the National Institute on Drug Abuse. It is the first time the federal government has directly paid for clinical studies of ibogaine.
The initiative builds on an executive order signed by President Trump in April that dedicated 50 million dollars to ibogaine research, reflecting growing political interest in alternative treatments for addiction and trauma.
“Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches.” — Michael Davis
What ibogaine is
Ibogaine is a naturally occurring compound found in the roots of the iboga shrub, native to Central Africa, where it has long been used in spiritual ceremonies. Under US law it is classified as a Schedule I controlled substance, meaning it is considered to have no accepted medical use and a high potential for abuse.

















